Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment
- PMID: 36730907
- PMCID: PMC10023267
- DOI: 10.1097/ADM.0000000000001087
Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment
Abstract
Objectives: The expansion of access to buprenorphine-naloxone (BUP-NAL) for the treatment of opioid use disorder (OUD) is critical to combat the overdose crisis. Evidence is lacking to guide providers on how to best promote BUP-NAL medication safety for their patients. This study assessed (1) the current medication storage practices among a sample of pregnant and parenting people receiving BUP-NAL for OUD; (2) the feasibility and acceptability of providing a lockbox for safe medication storage.
Methods: Pregnant and/or parenting patients receiving sublingual BUP-NAL in an outpatient OUD clinic were recruited between June and November 2021. Participants completed a baseline survey, received a lockbox, and a follow-up survey 3 to 8 weeks later. The primary outcome of current self-reported safe medication storage practice was defined by storing BUP-NAL in a locked/latched place "almost always" or "always" on the baseline survey. Outcomes were analyzed using simple proportions.
Results: Sixty-three participants completed the baseline survey, and 50 completed the follow-up survey. Baseline survey results indicated that only a quarter of patients (26.6%) were practicing safe BUP-NAL medication storage practices. At follow up, 93.6% of patients were using the lockbox provided by the study, 93.4% reported being satisfied with the lockbox, and most participants (89.3%) reported safe BUP-NAL medication storage practices.
Conclusions: Many pregnant and parenting patients with OUD receiving BUP-NAL do not store their medications safely. The provision of a lockbox as part of OUD treatment is a feasible, acceptable, and potentially effective harm reduction intervention.
Copyright © 2022 American Society of Addiction Medicine.
Conflict of interest statement
The authors report no conflicts of interest.
Figures

Similar articles
-
Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.Am J Drug Alcohol Abuse. 2018;44(6):604-610. doi: 10.1080/00952990.2018.1461877. Epub 2018 May 2. Am J Drug Alcohol Abuse. 2018. PMID: 29718715 Free PMC article. Clinical Trial.
-
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.J Subst Abuse Treat. 2022 Feb;133:108495. doi: 10.1016/j.jsat.2021.108495. Epub 2021 May 28. J Subst Abuse Treat. 2022. PMID: 34218992 Clinical Trial.
-
Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.J Addict Med. 2022 Mar-Apr 01;16(2):e97-e104. doi: 10.1097/ADM.0000000000000861. J Addict Med. 2022. PMID: 33973923 Clinical Trial.
-
Buprenorphine-Naloxone Film Versus Tablets for Opioid Use Disorder: CADTH Health Technology Review [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov. Report No.: RC1513. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov. Report No.: RC1513. PMID: 38320070 Free Books & Documents. Review.
-
Buprenorphine-naloxone therapy in pain management.Anesthesiology. 2014 May;120(5):1262-74. doi: 10.1097/ALN.0000000000000170. Anesthesiology. 2014. PMID: 24509068 Free PMC article. Review.
Cited by
-
Trends in maternal opioid use: Statewide differences by sociodemographic characteristics in Florida from 2000 to 2019.J Addict Dis. 2024 Oct-Dec;42(4):524-534. doi: 10.1080/10550887.2024.2302285. Epub 2024 Feb 18. J Addict Dis. 2024. PMID: 38369773
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical